Full-Time

Senior Director of Cloud Security

Updated on 9/10/2026

Deadline 9/18/26
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

Compensation Overview

$141.6k - $283.3k/yr

Delaware, USA + 4 more

More locations: Texas, USA | Philadelphia, PA, USA | Arizona, USA | New Jersey, USA

Remote

Bachelor's, Master's

Category
Cybersecurity
Required Skills
Kubernetes
Microsoft Azure
Incident Response
Threat modeling
Infrastructure as Code (IaC)
Vulnerability Analysis
SOC 2
AWS
Risk Management
Cryptography
DevOps
HIPAA
Google Cloud Platform

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A bachelor's degree in cybersecurity, computer science, information security, information systems, or a related field, or equivalent experience is required.
  • At least 12 years of directly related or relevant experience is required.
  • At least 8 years in a managerial capacity, preferably in information security, is required.
  • Knowledge of information technology risk management, information technology controls, cyber attack mitigation, enterprise information technology management, cloud security, network security, identity and access management, application security, service level maintenance, information security strategy continuity, threat modeling, and information security strategy standards including SOX, ISO 27001/27002, COBIT, ITIL, NIST, and PCI is required.
  • Knowledge of Microsoft Office Suite, security tools including CSPM, CWPP, CDR, CNAPP, SIEM, EDR, email security gateways, SOAR, firewalls, antivirus, VPN, IDS/IPS, and proxies is required.
  • Knowledge of open-source and commercial security testing tools, threat intelligence tools, and vulnerability testing tools is required.
Responsibilities
  • Define and execute the enterprise cloud security strategy aligned to corporate risk appetite and regulatory requirements.
  • Establish cloud security reference architectures, guardrails, and design patterns.
  • Lead cloud security governance across AWS, Azure, GCP, and strategic SaaS providers.
  • Own the cloud security policy framework and control standards aligned to NIST, ISO 27001, SOC 2, HITRUST, PCI, and HIPAA.
  • Present the cloud risk posture and roadmap to executive leadership and key stakeholders.
  • Lead cloud security architecture for landing zones and platform engineering, identity and access management including zero trust, network security and segmentation, encryption and key management, container and Kubernetes security, API security, and cloud-native application protection.
  • Establish secure-by-design and DevSecOps integration models in collaboration with Application Security Engineering and Secure SDLC engineers.
  • Drive an automation-first infrastructure-as-code and policy-as-code strategy in partnership with Platform Engineering and Application Security Engineering.
  • Oversee and partner with global support partners on CSPM, CWPP, CNAPP, DSPM, SSPM, and related platforms.
  • Drive critical alignment and integration with engineering and delivery leaders supporting capabilities such as CIEM, CASB, and SSE.
  • Partner with the SOC and Cyber Defense Engineering for cloud threat detection and response integration.
  • Oversee cloud logging, telemetry, and SIEM/SOAR integration.
  • Partner with Cyber Defense Engineering on the creation, validation, and testing of cloud incident response engineering playbooks.
  • Partner with Risk Management and other key stakeholders to establish vulnerability management and misconfiguration remediation pipelines.
  • Track and reduce enterprise cloud risk metrics.
  • Secure multi-cloud architectures across AWS, Azure, and GCP.
  • Ensure consistent controls across on-premises, private cloud, and SaaS ecosystems.
  • Support mergers and acquisitions integrations and divestitures with cloud security assessments and rapid control deployment.
  • Ensure compliance with global regulatory regimes including HIPAA, GDPR, SOX, and FDA/GxP where applicable.
  • Enable audit readiness and continuous control monitoring.
  • Partner with Legal and Privacy on data residency and cross-border cloud risks.
  • Build and lead a global team of cloud security architects and engineers.
  • Develop succession planning and technical career paths.
  • Establish KPIs, OKRs, and performance dashboards.
  • Manage enterprise financial planning and management.
  • Foster collaboration with platform engineering, SRE, and DevOps teams.
  • Follow information security trends and work with executive leadership to strategize and recommend changes and updates to the company.
Desired Qualifications
  • A master's degree in cybersecurity, computer science, information security, information systems, or a related field, or equivalent experience is preferred.
  • Certified Cloud Security Professional certification.
  • Certified Information Systems Security Professional certification.
  • Certification in Information Security Strategy Management.
  • Microsoft Certified: Cybersecurity Architect Expert (SC-100).
  • Information Technology Infrastructure Library certification.
  • Offensive Security Certified Professional certification.
  • Project Management Professional certification.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.